Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

The FDA approves NuPathe's (PATH) Zecuity for the acute treatment of migraine with or without...

  • Thursday, January 17, 7:56 PM ET
    The FDA approves NuPathe's (PATH) Zecuity for the acute treatment of migraine with or without aura in adults. The drug is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin. Shares surge +18% after resuming trade following an earlier halt.
Track new comments on this story

This news story has 3 comments:

  •  
    I bought some PATH AH @3.60 believing that it is a sreaming buy. Could easily double/triple from here. I don't see a major downside @ these price levels. Let's see how this goes.
    18 Jan, 06:10 AM Reply Like
  •  
    Good call HS. Should be announcing a launch partner in the next few weeks. This stock should be above $8 if valued fairly!
    20 Jan, 02:28 PM Reply Like
  •  
    Zecuity sounds really unique. According to http://bit.ly/YkOssW, the medicine is actually delivered by a battery powered pack. It sounds like a great help for those who suffer from migraines.
    22 Jan, 11:38 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »